Summary
Irtemazole 12.5 to 50 mg in 6 healthy, normouricaemic subjects caused a maximal decrease in plasma uric acid (after 8 to 12 h) of 46.5%. The uricosuric effect began during the first 60 min after drug administration and it lasted for 7 to 24 h. Renal uric acid excretion returned to its base line value after 8 to 16 h and uric acid clearance after 10.0 to 12.0 h.
Doses of irtemazole between 12.5 and 37.5 mg produced a dose-related rise in the uricosuric effect. There was no essential difference between the uricosuric effect of 37.5 mg and 50 mg irtemazole. The D50 dose (that producing a half-maximal effect) was between 16.3 mg and 34.2 mg, (average 24.7 mg).
The value of irtemazole in the management of hyperuricaemia and gout remains to be determined.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gresser U, Zöllner N (1989) A new uricosuric substance 5-[(1H-imidazol-1-yl) phenylmethyl]-2-methyl-1H-benzimidazole (C18H16N4). Klin Wochenschr 67: 645
Gresser U, Zöllner N (1989) Uricosuric effect of irtemazole in healthy subjects. Klin Wochenschr 67: 971–975
Praetorius E, Poulsen H (1953) Enzymatic determination of uric acid with detailed directions. Scand J Clin Lab Invest 5: 273–279
Zöllner N (1963) Eine einfache Modifikation der enzymatischen Harnsäurebestimmung. Normalwerte in der deutschen Bevölkerung. Z Klin Chem 1: 178–182
Heel RC, Brogden RN, Speight TM, Avery GS (1977) Benzbromarone: A review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs 14: 349–366
Löffler W (1982) Urikosurika. In: Zöllner N (ed) Hyperurikämie und Gicht 5. Springer, Berlin Heidelberg New York
Jain AK, Ryan JR, McMahon FG, Noveck RJ (1974) Effect of single oral doses of benzbromarone on serum and urinary uric acid. Arthritis Rheum 17: 149–157
Gröbner W, Zöllner N (1989) Differentialindikation Urikosurika und Allopurinol. Klin Wochenschr 67: 313–315
Zöllner N, Gröbner W (1971) Über Uricosurica. Arzneim Forsch (Drug Res) 21: 1500–1503
Zöllner N, Dofel W, Gröbner W (1970) Die Wirkung von Benzbromaronum auf die renale Harnsäureausscheidung Gesunder. Klin Wochenschr 48: 426–432
Cunningham RF, Israili ZH, Dayton PG (1981) Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 6: 135–151
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gresser, U., Kamilli, I., Kronawitter, U. et al. Uricosuric effect of different doses of irtemazole in normouricaemic subjects. Eur J Clin Pharmacol 38, 489–491 (1990). https://doi.org/10.1007/BF02336689
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02336689